ARA-290 10mg

ARA-290 10mg

ARA-290 peptide is a synthetic research compound derived from erythropoietin (EPO), studied for its anti-inflammatory, neuroprotective, and microvascular benefits in cellular models.

ARA-290 peptide, also known as Cibinetide, is a small synthetic peptide derived from erythropoietin (EPO). Unlike EPO, which stimulates red blood cell production, ARA-290 selectively targets the innate repair receptor (IRR) to promote tissue protection and reduce inflammation without affecting hematopoiesis.

This makes ARA-290 an advanced research compound for scientists studying inflammatory modulation, neuropathic pain, and microvascular repair. At GRAM Peptides, each batch of ARA-290 peptide is pharmacist-formulated and third-party tested for purity, ensuring dependable results for laboratory use.

Understanding ARA-290

ARA-290 is an 11-amino-acid peptide modeled after the helix-B surface of erythropoietin. It was designed to maintain EPO’s protective effects while eliminating its blood-stimulating activity.

Research shows ARA-290 interacts specifically with the EPOR-CD131 complex, activating intracellular pathways linked to anti-inflammatory signaling and tissue recovery. Through this mechanism, ARA-290 peptide has been studied for its potential in conditions involving:

• Peripheral neuropathy and small-fiber nerve damage
• Autoimmune and inflammatory disorders
• Ischemia-reperfusion injury
• Diabetes-related vascular complications

This receptor-targeted selectivity has made ARA-290 an attractive model for next-generation cytokine-mimetic peptides.

Benefits Observed in Research

Studies suggest ARA-290 peptide may provide the following laboratory-observed effects:

• Anti-Inflammatory Action – Reduces cytokine signaling and immune activation without suppressing healthy immune response.
• Nerve Protection – Supports small-fiber nerve regeneration and reduced pain response in animal models.
• Microvascular Repair – Promotes improved endothelial function and capillary perfusion.
• Reduced Oxidative Stress – Decreases reactive oxygen species and inflammatory byproducts.
• Improved Cellular Recovery – Enhances healing following metabolic or ischemic stress.

These potential effects make ARA-290 valuable for research in neuroinflammation, pain modulation, and tissue repair.

The Science Behind ARA-290 Peptide

ARA-290’s action at the innate repair receptor triggers phosphorylation of intracellular proteins such as JAK2 and STAT3, leading to downstream activation of PI3K and Akt pathways. These cascades are associated with:

• Decreased inflammatory mediator production
• Increased nitric oxide bioavailability for vascular support
• Protection against mitochondrial and oxidative damage
• Enhanced nerve regeneration in experimental neuropathy

Unlike traditional EPO signaling, this pathway does not stimulate red blood cell formation, making ARA-290 peptide a safer and more targeted research molecule for anti-inflammatory and neuroprotective studies.

For published data, visit PubMed Research on ARA-290.

Why Choose GRAM Peptides

• Pharmacist-Formulated – Developed by a licensed compounding pharmacist with 20+ years of experience.
• USA-Made – Manufactured in ISO-compliant facilities with precision standards.
• Third-Party Tested – Verified for purity, potency, and identity.
• Transparent Documentation – Certificates of Analysis available upon request.

GRAM Peptides ensures reliability and reproducibility for all research applications.

Research Applications

ARA-290 peptide is being studied in several promising areas of biomedical science:

• Neuropathy & Nerve Repair – Peripheral and diabetic neuropathy models.
• Inflammatory Disorders – Research on cytokine modulation and immune regulation.
• Microcirculation – Endothelial health and capillary perfusion under oxidative stress.
• Ischemic Injury – Organ and tissue protection following reduced oxygen supply.
• Autoimmune Studies – Modulation of immune overactivity without immunosuppression.

Researchers often compare ARA-290 peptide to regenerative compounds such as BPC-157 and TB-500.

Frequently Asked Questions

What is ARA-290 peptide?
A synthetic 11-amino-acid peptide modeled after erythropoietin, studied for its tissue-protective and anti-inflammatory properties.

Is ARA-290 FDA-approved?
No. It is for Research Use Only (RUO) and not for human or veterinary use.

How does ARA-290 differ from EPO?
Unlike erythropoietin, ARA-290 does not increase red blood cell count, focusing solely on repair and anti-inflammatory pathways.

Can ARA-290 be combined with other research peptides?
Yes. It is frequently used in studies alongside regenerative compounds like BPC-157 and TB-500 to explore synergistic healing mechanisms.

Related Peptides for Inflammation & Repair

• BPC-157 Peptide – Studied for gut, tendon, and tissue healing.
• TB-500 Peptide – Researched for cellular regeneration and wound repair.
• GHK-Cu Peptide – Explored for anti-inflammatory and regenerative properties.

Disclaimer

ARA-290 peptide is sold strictly for Research Use Only (RUO). Not for human consumption, medical, or veterinary use.

ARA-290 peptide vial GRAM Peptides